repetitive transcranial magnetic stimulation (rTMS)
repetitive transcranial magnetic stimulation (rTMS): Repetitive transcranial magnetic stimulation (rTMS) is a recently developed neuromodulation technique.
Study summary
This randomized controlled trial (RCT) is the first to evaluate the efficacy and safety of a multi-target TMS protocol targeting the right orbitofrontal cortex (R-OFC), left dorsolateral prefrontal cortex (L-DLPFC), and left inferior parietal lobule (L-IPL) for negative symptoms of schizophrenia.
Eligibility
Sex
ALL
Min age
16 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria:
1. Outpatients or inpatients at the Department of Psychiatry, Shanghai Mental Health Center;
2. Meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for first-episode schizophrenia (diagnosed using the Structured Clinical Interview for DSM-5, SCID-5); disease duration less than 5 years at enrollment;
3. Male or female aged 16-45 years;
4. Education duration ≥ 9 years;
5. Stable medication regimen for at least 6 weeks prior to baseline visit and throughout the study period; psychiatric symptoms generally stable within 1 month prior to baseline visit;
6. Participants and their guardians can understand and sign written informed consent;
7. Total score on the PANSS Negative Symptom subscale (PANSS-N) \> 15, and at least one item score ≥ 3.
Exclusion Criteria:
1. Current or lifetime psychiatric disorders as determined by SCID-5 assessment;
2. Severe or unstable physical illnesses, including: neurological disorders (delirium, dementia, stroke, epilepsy, migraine, etc.), congestive heart failure, angina pectoris, myocardial infarction, arrhythmia, hypertension, hyperglycemia, malignant tumors, and immunocompromised conditions;
3. Alcohol abuse within 30 days prior to the study or alcohol/drug dependence within 6 months prior to the study; participation in any clinical trial within 30 days prior to baseline;
4. Pregnant or breastfeeding women;
5. Intellectual disability (IQ \< 70);
6. No history of modified electroconvulsive therapy (mECT) within the past 6 months.
Primary outcome measure(s)
Change in severity of negative symptoms before and after TMS intervention, i.e., change in Positive and Negative Syndrome Scale - Negative subscale (PANSS-N) — Negative symptoms will be measured at baseline (Day-4±2), immediately after the 50th session of TMS (Day 14), and at 2 weeks (Day 28), and 4 weeks ( Day 42) after completion of TMS treatment. Schizophrenia negative symptoms assessed using Positive and Negative Syndrome Scale - Negative subscale (PANSS-N)
Minimum value: 7 (each of the 7 items scored 1 = absent)
Maximum value: 49 (each of the 7 items scored 7 = extreme)
Higher score indicates: Worse outcome (greater severity of negative symptoms)
Trial sites (1)
Facility
City
Region
Status
Shanghai Mental Health Center
Shanghai
Shanghai Municipality
More Shanghai Mental Health Center trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.